Skip to main content
SpringerLink
Log in

Antiinflammatory Drug-Induced Small Intestinal Permeability: The Rat Is a Suitable Model

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Excretion of orally administrated 51Cr-EDTA as a marker of small intestinal permeability (a proposed prerequisite for human enteropathy) is increased by corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs). We have investigated the suitability of the rat as an animal model of small intestinal permeability using orally administered 51Cr-EDTA. We dosed Sprague-Dawley rats with NSAIDs and corticosterone followed by 51Cr-EDTA under conditions reported for humans and measured urinary excretion of the marker. In control rats, the urinary excretion of 51Cr-EDTA exhibited a skewed-to-the-left frequency distribution curve with a median of 2.13% of the dose. No sex-related differences were noticed in the baseline permeability. In male rats, single therapeutically equivalent doses of indomethacin, flurbiprofen, ibuprofen, naproxen, diclofenac, sulindac, nambumetone, and corticosterone, increased the intestinal permeability by different extents with indomethacin eliciting the maximum effect, and the last four drugs showing minimal potencies. Therapeutically relevant doses of aspirin did not have any significant effect. The increase in permeability was dependent upon the NSAIDs dose. Administration of glucose/citrate, misoprostol and sulfasalazine significantly reduced the effect of indomethacin. Misoprostol antagonized the effect of naproxen but H2-antagonists and sucralfate did not. All the above observations made in the rat were similar to those previously reported for humans. Thus the rat is a suitable model for studies of small intestinal permeability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. K. D. Rainsford. Mechanisms of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Scand. J. Gastroentrol. 24:9–16 (1989).

    Google Scholar 

  2. I. Bjarnason, J. Hayllar, A. J. Macpherson, and A. S. Russell. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 104:1832–1847 (1993).

    Google Scholar 

  3. A. J. Morris, R. Madhok, R. D. Sturrock, H. A. Capell, and J. F. MacKenzie. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet 337:520 (1991).

    Google Scholar 

  4. I. Bjarnason, P. Williams, P. Smethurst, T. J. Peters, and A. J. Levi. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 27:1292–1297 (1986).

    Google Scholar 

  5. I. Bjarnason, A. So, A. J. Levi, T. J. Peters, D. Williams, G. D. Zanelli, J. M. Gumpel, and B. Ansell. Intestinal permeability and inflammation in rheumatoid arthritis: Effects of non-steroidal anti-inflammatory drugs. Lancet i:1171–1173 (1984).

    Google Scholar 

  6. R. T. Jenkins, R. T. Rooney, D. R. Jones, J. Bienenstock, and R. L. Goodacre. Increased intestinal permeability in patients with rheumatoid arthritis: a side-effect of oral non-steroidal antiinflammatory drug therapy? Br. J. Rheumatol. 26:103–107 (1987).

    Google Scholar 

  7. L. Aabakken, S. Larsen, and M. Osnes. Sucralfate for prevention of naproxen-induced mucosal lesions in the proximal and distal gastrointestinal tract. Scand. J. Rheumatology 18:361–368 (1989).

    Google Scholar 

  8. L. Aabakken. 51Cr-Ethylenediaminetetraacetic acid absorption test: methodological aspects. Scand. J. Gastroenterol. 24:351–358 (1989).

    Google Scholar 

  9. F. L. Lanza, G. L. Royer, R. S. Nelson. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N. Engl. J. Med. 303:(3)136–138 (1980).

    Google Scholar 

  10. K. D. Rainsford. In R. A. Greenwald and H. S. Diamond (eds.), In Handbook of Animal Models for Rheumatic Diseases, CRC Press, Boca Raton, 1988.

    Google Scholar 

  11. I. Bjarnason, P. Smethurst, A. J. Levi, and T. J. Peters. Intestinal permeability to 51Cr-EDTA in rats with experimentally induced enteropathy. Gut 26:579–585 (1985).

    Google Scholar 

  12. J. K. Ramage, R. T. Jenkins, R. H. Hunt, and M. H. Perdue. Permeability of inflamed jejunum to 51Cr-EDTA in the in vivo rat. Gastroenterology A1261 (1988).

  13. H. Mielants, S. Goemaere, M. De Vos, K. Schelstraete, K. Goethal, M. Maertens, C. Ackerman, and E. M. Veys. Intestinal mucosal permeability in inflammatory rheumatic diseases. I. Role of antiinflammatory drugs. J. Rheumatol. 18:389–393 (1991).

    Google Scholar 

  14. I. Bjarnason, P. Smethurst, C. G. Fenn, C. E. Lee, I. S. Menzies, and J. Levi. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig. Dis. and Sci. 34:407–411 (1989).

    Google Scholar 

  15. G. R. Davies, and D. S. Rampton. The pro-drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Therap. 5:593–598 (1991).

    Google Scholar 

  16. G. R. Davies, M. E. Wilkie, and D. S. Rampton. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig. Dis. and Sci. 38(3):417–425 (1993).

    Google Scholar 

  17. I. Bjarnason, P. Smethurst, A. Macpherson, F. Walker, J. C. McElnay, P. Passmore, and I. S. Menzies. Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 102:1546–1550 (1992).

    Google Scholar 

  18. A. K. Banerjee, R. Sherwood, J. A. Rennie, and T. J. Peters. Sulphasalazine reduces indomethacin induced changes in small intestinal permeability in man. Brit. Soc. Gast. A 593 (1991).

  19. I. Bjarnason, B. Fehilly, P. Smethurst, I. S. Menzies, and A. J. Levi. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut. 32:275–277 (1991).

    Google Scholar 

  20. L. Aabakken, and M. Osnes. 51Cr-Ethylenediaminetetraacetic acid absorption test. Effects of naproxen, a non-steroidal, anti-inflammatory drug. Scand. J. Gastroenterol. 25:917–924 (1990).

    Google Scholar 

  21. R. T. Jenkins, P. J. Rooney, and R. H. Hunt. Increased bowel permeability to [51Cr]EDTA in controls caused by Naproxen is not prevented by cytoprotection. Arthritis. Rheum. 31:(Suppl 1)R11 (1988).

    Google Scholar 

  22. L. Aabakken, S. Larsen, and M. Osnes. Cimetidine tablets or suspension for the prevention of gastrointestinal mucosal lesions caused by non-steroidal, anti-inflammatory drugs. Scand. J. Rheumatology 18:369–375 (1989).

    Google Scholar 

  23. L. Aabakken, B. A. Bjørnbeth, R. Weberg, L. Vikmoen, S. Larsen, and M. Osnes. NSAID-associated gastroduodenal damage does famotidine protection extend into the mid and distal duodenum? Aliment. Pharmacol. Therap. 4:295–303 (1990).

    Google Scholar 

  24. M. Rowland, and S. Riegelman. Pharmacokinetics of acetylsalicylic acid and salicylic acid after iv administration in man. J. Pharm. Sci. 2:1313–1319 (1968).

    Google Scholar 

  25. J. A. Mitchell, P. Akarasereenont, C. Thiemermann, R. J. Flower, and J. R. Vane. Selectivity of non-steroidal antiinflammatory drugs as inhibitors of constitutive an inducible cyclooxygenase. Proc. Natl. Acad. Sci. 90:11693–11697 (1994).

    Google Scholar 

  26. D. W. Powell. Barrier function of epithelia. American Journal of Physiology 266:275–288 (1981).

    Google Scholar 

  27. K. D. Rainsford. Prevention of indomethacin-induced gastrointestinal ulceration in rats by glucose-citrate formulation: Role of ATP in mucosal defenses. Br. J. Rheumatol. 26:(suppl 2):81 (1980).

    Google Scholar 

  28. I. Bjarnason, T. J. Peters, and N. Veall. A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labeled EDTA absorption test. Lancet i:323–325 (1993).

    Google Scholar 

  29. L. O. Simpson. NSAIDs and the leaky gut. Lancet i:218 (1985).

    Google Scholar 

  30. I. Bjarnason, G. Zanelli, T. Smith, P. Smethurst, A. B. Price, M. J. Gumpel, and A. J. Levi. The pathogenesis and consequence of non-steroidal anti-inflammatory drug induced small intestinal inflammation. Scand. J. Rheumatol. suppl. 64:55–62 (1987).

    Google Scholar 

Download references

Author information

Author notes

  1. Matthew R. Wright

    Present address: College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada, B3H 3J5

Authors and Affiliations

  1. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

    Neal M. Davies, Matthew R. Wright & Fakhreddin Jamali

Authors
  1. Neal M. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew R. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fakhreddin Jamali
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davies, N.M., Wright, M.R. & Jamali, F. Antiinflammatory Drug-Induced Small Intestinal Permeability: The Rat Is a Suitable Model. Pharm Res 11, 1652–1656 (1994). https://doi.org/10.1023/A:1018978308752

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018978308752

Search

Navigation